Search

Search Constraints

You searched for: Author/Creator Macarulla, T

Search Results

1. 126OOlaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. (24th November 2019)

2. 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC). (15th December 2019)

3. 92PVall d'Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI). (23rd October 2018)

4. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. (28th September 2019)

5. LBA-001Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. (2nd July 2019)

6. LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. (23rd October 2018)

7. O-001An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2nd July 2019)

8. O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. (2nd July 2019)

9. P-160Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first‐line chemotherapy in routine practice. (20th June 2018)

10. P-160Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first‐line chemotherapy in routine practice. (20th June 2018)